

How to select the Most Appropriate Device for CAS?

Oscar Mendiz. MD. FACC. FSCAI Head Interventional Cardiology Department Board of Directors Members Hospital & Favaloro University

www.fundacionfavaloro.org

Cerebral Protection During CAS

Multifactorial:

- Operators (training, experience, multidisciplinary team, etc.)
- Patients selection (Symptoms, age, DBT, plaque characteristics, aortic arch, bilateral disease, medications, previous lacunar defects, etc, etc).
- Carotid Angioplasty Technique (carotid engagement, wires, guiding, balloons, pre & post dilatation, post PTA care, radial approach, etc)
- Cerebral Protection Devices. Which one for which lesion.

Stent Design (Closed vs. open cell ?)





Cerebral Protection Strategies



Cerebral Protection Devices & Personal Experience

Distal Occlusive Balloon:

Theron System. GuardWire Plus. PercuSurge™. *Medtronic.* Twin One. Mynvasis

Filters:

Filter Wire EZ [™]. Boston Scientific. Angioguard [™]. Cordis J&J. Spider [™] Accunet [™]. Abboth EmboShield [™]. Abboth. Rubicon. Boston Scientific. Others.

Reversal Flow and Flow Blockage:

PAES ®. Parodi Anti-Embolism System. *Gore* MOMA. *Medtronic*.





Distal Occlusive Balloons: GuardWire Plus







PercuSurge GuardWire System.

Fundación Favaloro Experience. O Mendiz, et al.







Distal Occlusive Balloons

Advantages:

Low profile. Block all possible particles embolization after crossing

Disadvantages:

Particles dislodgements the flow; Proximal is better Potential district to block the flow; Proximal is used in f you are going to block the section or spasm where the Wire's lack of support (Guardwire plus) Not friendly to use (Guardwire plus) Stenting without protection (TwineOne)





Distal Occlusive Balloons

•

RCA



Not Good Candidates:

- Contralateral occlusion or critical stenosis.
- Willis' Circle abnormalities.
 - Subtotal obstructions Tortuous ICA. High or intracraneal lesions. Beginners.



Filter Devices

Over-the-wire Filters:

Advantage: easy to cross tight lesion and curves with bare wires. Disadvantage: more steps for using.

On-the-wire Filters:



Advantage: One step positioning Disadvantage: Difficult to cross very tortuous vessel or tight lesions.





Filter Devices

Concentric Filters:



Disadvantage: they need an straight landing zone. More rigid.

Eccentric Filters:



Self Centering Filters:





Advantage: shorter straight landing zone. More flexible. Better artery wall appositioning.





Fundación Favaloro

EPI Filter Wire Long lesions at CCA & ICA



EPI Filter Wire









Fundación Favaloro

Second Surgical Restenosis post CEA:







Straight Vessel, Concentric & Fibrotic Plaque; Ideal for Filter







Ulcerated lesion but Contralateral Occlusion Easier with filter













Soft, eccentric, ulcerated plaque <u>at the bifurcation</u>

Filter + Closed Cell Stent







Proximal Occlusion or Over the Wire Filters





Better for over the wire filter (Emboshield-Spider)

Fundación Favaloro

Subtotal occlusion with plaque at the CCA











Filter Devices

Advantages:
 Maintain the ICA flow.
 Easy to use.
 Profile ?.

Disadvantages:





Allow small particles flow (±80-120 mµ).
Particles dislodgement when crossing.
Potential trauma at distal landing zone. (dissection or spasm where the filter is deployed).
Profile ?.
Flexibility ?





Crossing Failure: Epi Filter Wire

Failure to cross the lesion:



Failure to cross the lesion: EpiFilter (BSC) & Roadrunner .018" (Cook) It was crossed with a coronary guidewire (BMW .014".Guidant)





Fundación Favaloro

Crossing Failure

"On the wire"



"Over the wire"





Ideal Case for Proximal Protection Device

Fundación Favaloro

Distal Protection Device Complication:







Distal nInternal Carotid Artery Dissection







EPIC FiberNet Embolic Protection System

FiberNet[®] system is a novel EPD that incorporates the ability to allow flow during the procedure (filter), capability to capture small particles (occlusion balloon) and has deliverability of standard coronary guidewire.







EPIC FiberNet[®] EPS





Fiber-based filter conforms to asymmetrical vessels

No delivery system required with a crossing profile 1.7 to 2.9 F











Gentileza. Dr Shönhold

Rationale for Proximal Protection Devices

- Pass lesions unprotected (balloon-filters)
- Onreliable wall apposition (filters)
- Emboli passing through the filter
- Need for suitable landing zone (balloon-filter)
- Potential trauma to the landing zone (balloonfilter).
- Difficult to negotiate tortuous anatomies, tight lesions.





Main Indication:

Soft, tight, eccentric plaque without bifurcation compromise and good contralateral circulation









Proximal Flow Blockage and Closed Cell Stent



Soft, tight, eccentric plaque without bifurcation compromise and good contralateral circulation





Spontaneous ICA Disection









Proximal Flow Blockage

Proximal Protection Devices

First choice for:

- Soft ulcerated plaque ?
- High lesions
- Critical stenosis
- Intracraneal associated lesions
- Lack of distal landing zone for DPD (tortuosity, lesion, high plaque, etc).





Protection Devices Differences

Reversal Flow / Flow Blockage Systems

Advantages:

Lesions are crossed under protection. No particles embolization through ECA.

Disadvantages:

Can not be well tolerated (contralateral disease, Willis circle abnormalities) Difficult to use at bifurcational lesions. Potential dissection, spasm or trauma where the balloon is inflated. Look unfriendly to use.





Which Protection Device is Better?

Lack of appropriate level of evidence.

- Not adequate randomized trial.
- Most of the information provided by single center, small, industry sponsored or based on operators experience.
- However, different patients and lesions seem to be better approached by an specific device based on operators experience and device.



Finol et al. J Endovasc Ther 2008;15:177-185. El-Koussy et al. J Endovasc Ther 2007;14:293-303 Iyer V, et al. J Vasc Surg 2007;48:251-258



CLINICAL INVESTIGATION

J ENDOVASC THER 2008;15:249-262

Carotid Artery Stenting With Patient- and Lesion-<u>Tailored Selection of the Neuroprotection</u> System and Stent Type: Early and 5-Year Results From a Prospective Academic Registry of 535 Consecutive Procedures (TARGET-CAS)

Piotr Pieniazek, MD, PhD¹; Piotr Musialek, MD, PhD¹; Anna Kablak-Ziembicka, MD, PhD¹; Lukasz Tekieli, MD¹; Rafal Motyl, MD, PhD²; Tadeusz Przewlocki, MD, PhD¹; Zbigniew Moczulski, MD³; Mieczyslaw Pasowicz, MD, PhD³; Andrzej Sokolowski, MD, PhD⁴; Agata Lesniak-Sobelga, MD, PhD¹; Krzysztof Zmudka, MD, PhD⁵; and Wieslawa Tracz, MD, PhD¹

What Practical Factors Guide the Choice of Stent and Protection Device during Carotid Angioplasty?*

M. Bosiers,^{1*} K. Deloose,¹ J. Verbist² and P. Peeters² Eur J Vasc Endovasc Surg 35, 637–643 (2008)

The importance of angioplasty and stenting in the treatment of carotid artery disease cannot be underestimated. Successful carotid stenting does not only depend of the operator's skills and experience, but also an adequate selection of cerebral protection devices and carotid stents can help avoiding neurological complications. A broad spectrum of carotid devices is cur-

Safety, efficacy and long-term durability of endovascular therapy for carotid artery disease: the tailored-Carotid Artery Stenting Experience of a single high-volume centre (tailored-CASE Registry)

Alberto Cremonesi¹*, MD; Shane Gieowarsingh², MBBS; Barbara Spagnolo³, PhD; Raffaella Manetti¹, MD; Armando Liso¹, MD; Alessandro Furgieri¹, MD; Maria Cristina Barattoni³, MSc; Luca Ghetti³, MSc; Luigi Tavazzi⁴, MD; Fausto Castriota¹, MD







P Pieniazek, et al.

2008;15:249-262

Fundación Favaloro



J ENDOVASC THER

2009; Dec, 16/6/744



1717 CAS procedures (01.2001 - 11.2012) 1549 pts; (50.1%) symptomatic

675 high risk lesion - 39.3%

PROXIMAL EPD in 618 CAS (35.9%) In 2012 53% !



L





Kraków experience: Tailored CAS, Pieniazek & multidyscyplinarny team

1717 CAS procedures (01.2001 - 11.2012) 1549 pts; (50.1%) symptomatic

| a an | Proximal NPS (618 CAS) | distal NPS (1099 CAS) | p |
|--|---------------------------|--------------------------|---------|
| High-risk lesion | 92.1% | 9.7% | p<0,001 |
| Direct stenting | 29.8% | 63.7% | p<0.001 |
| Closed-cell-design stents | 83.8% | 68.1% | p<0.001 |
| Residual stenosis by QCA | 11 ± 9% (0-40) | 10 ± 8 (0-30) | NS |
| Restenosis >50% (US, CT) | 1.7% | 2.1% | NS |





Kraków experience: Tailored CAS, Pieniazek & multidyscyplinarny team

1717 CAS procedures (01. 2001 - 11. 2012) 1549 pts (50.1%) symptomatic

| RESULTS 30-days | Proximal protection | Distal protection | |
|---|---------------------|-------------------|---------|
| No. of CAS | 618 | 1099 | |
| death | 0.48% (3/618) | 1.0% (11/1099) | p=0,254 |
| major/disabling stroke | 0.3% (2/618) | 0% | p=0,059 |
| any stroke | 1.29% (8/618) | 1.36% (15/1099) | p=0,903 |
| death/disabling stroke | 0.8% (5/618) | 1.0% (11/1099) | p=0,691 |
| death/any stroke | 1.78% (11/618) | 2.37% (26/1099) | p=0,422 |
| Long-term (4.6 +/-2.8 y) follow-up ipsilateral stroke | 2.7% (16/618) | 4.0% (43/1099) | p=0,148 |
| Long-term (4.6 +/-2.8 y) follow-up death | 5.4% (33/618) | 9,0% (99/1099) | p=0,062 |

Journal of the American College of Cardiology © 2012 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 59, No. 15, 2012 ISSN 0735-1097/\$36.00 doi:10.1016/j.jacc.2011.11.035

FOCUS ISSUE: TRANSCATHETER CARDIOVASCULAR THERAPEUTICS

The PROFI Study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting)

A Prospective Randomized Trial

Klaudija Bijuklic, MD, Andreas Wandler, MD, Fadia Hazizi, MD, Joachim Schofer, MD, PHD Hamburg, Germany





Proximal Protection vs. Filter: The PROFI Trial

Diffusion-weighted MRI evaluation CAS Ptes randomized to PPD (31) vs. Filter D (31)



The number (median [range]: 0 [0 to 4] vs. 2 [0 to 13]), p=0.0001 The volumen (0 [0 to 0.84] cm³ vs. 0.47 [0 to 2.4] cm³), p=0.0001



Bijuklic K. Et al. J Am Coll Cardiol 2012;59:1383-9



Proximal Protection vs. Filter: The PROFI Trial

Diffusion-weighted MRI evaluation CAS Ptes randomized to PPD (31) vs. Filter D (31)



years of age are displayed.



Bijuklic K. Et al. J Am Coll Cardiol 2012;59:1383-9



CAS complications:

Is it all about Protection Devices?Which is the Importance of Stent Design?





Post-procedural phase: the dark side of stents



Modified from, A. Cremonesi et al. – EuroIntervention, December 2005



"Free cell area" based analysis



Based on Houdart, Cirse 2005 and Cremonesis, SOLACI 2007



Carotid Stent Design: Cell size comparison

| W.L. Gore and Associates* | Abbott Laboratories | Abbott Laboratories | Boston Scientific Corporation | e∨3 Inc./ Covidien | Cordis Corporation | Medtronic, Inc./ Invatec |
|---------------------------------------|------------------------|------------------------|-------------------------------------|--------------------------|-----------------------|-------------------------------|
| GORE [®] Carotid Stent | ACCULINK® RX DEVICE | XACT® DEVICE | WALLSTENT® MONORAIL® DEVICE | PROTÉGÉ RX® DEVICE | PRECISE® DEVICE | CRISTALLO IDEALE DEVICE |





"Free cell area" based analysis

Post-procedural neuro events: Symptomatic population



SPACE TRIAL:

Higher Neurologic Events with Open Cell Design

Table 4. Influence of Different Stent Types on OE Rate

| Stent | Wallstent | Acculink | Precise |
|---------------------|-----------------|------------------|-------------------|
| No. of patients | 436 | 92 | 35 |
| Pat. with OE | 24 | 9 | 5 |
| 0E rate (95% Cl) | 5.5% (3.6–8.1%) | 9.8% (4.6–17.8%) | 14.3% (4.8–30.3%) |
| Combined 0 | | | 11.0% (6.2–17.8%) |



Jansen, et al. Stroke 2009;40:841



Do device characteristic impact outcome in carotid stenting?

Adverse events at 30 days in symptomatic

Stent Design

Filter Design





Hart JP. Et al. J Vasc Surg 2006;44:725-30

Fundación Favaloro

GORE[®] Carotid Stent:



Open Cell Nitinol Frame

- Closed Cell 500 µ lattice on outside of Frame
- Permanently Bound CBAS Heparin on all device Surfaces

SCAFFOLD Trial is ongoing



Modified from J Laird, Linc 2014



Which is the Best Strategy for CAS?

Although there are not good randomized trials: Tailored CAS using different Protection Devices and Stent Design has been shown as a good strategy to treat more complex patients without increasing the complication rate

New approaches (radial), Proximal Protection Devices and new stent design may improve CAS outcomes.





Thank you for your attention



omendiz@ffavaloro.org



Fundación Favaloro